Candel Therapeutics Shares Owned By Institutions vs. Return On Asset

CADL Stock  USD 4.43  0.08  1.77%   
Based on Candel Therapeutics' profitability indicators, Candel Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Candel Therapeutics' ability to earn profits and add value for shareholders. The value of Price To Sales Ratio is estimated to slide to 450.93. The value of EV To Sales is estimated to slide to 37.90. At this time, Candel Therapeutics' Accumulated Other Comprehensive Income is quite stable compared to the past year. Total Other Income Expense Net is expected to rise to about 640 K this year, although the value of Net Interest Income is projected to rise to (28.5 K).
For Candel Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Candel Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Candel Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Candel Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Candel Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Candel Therapeutics Return On Asset vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Candel Therapeutics's current stock value. Our valuation model uses many indicators to compare Candel Therapeutics value to that of its competitors to determine the firm's financial worth.
Candel Therapeutics is rated below average in shares owned by institutions category among its peers. It is rated below average in return on asset category among its peers . The value of Return On Assets is estimated to slide to -0.97. Comparative valuation analysis is a catch-all technique that is used if you cannot value Candel Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Candel Return On Asset vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Candel Therapeutics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
22.53 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Candel Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.52
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Candel Return On Asset Comparison

Candel Therapeutics is currently under evaluation in return on asset category among its peers.

Candel Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Candel Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Candel Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Candel Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Candel Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-30 K-28.5 K
Interest Income2.1 M1.2 M
Operating Income-38.4 M-40.3 M
Net Loss-31.9 M-33.5 M
Income Before Tax-37.9 M-39.8 M
Total Other Income Expense Net452 K640 K
Net Loss-16.9 M-17.8 M
Net Loss-37.9 M-39.8 M
Income Tax Expense-14.3 M-13.6 M
Non Operating Income Net Other-9.4 M-9.8 M
Change To Netincome-12.4 M-11.8 M
Net Loss(1.31)(1.38)
Income Quality 0.90  0.70 
Net Income Per E B T 0.18  0.17 

Candel Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Candel Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Candel Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Candel Therapeutics' important profitability drivers and their relationship over time.

Use Candel Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Candel Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Candel Therapeutics Pair Trading

Candel Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Candel Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Candel Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Candel Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Candel Therapeutics to buy it.
The correlation of Candel Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Candel Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Candel Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Candel Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Candel Therapeutics position

In addition to having Candel Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Social Domain Thematic Idea Now

Social Domain
Social Domain Theme
New or established large and mid-sized companies that are involved in the social media industry, including entities that provide web-based or mobile media applications and services across across large segment of population in multiple geographical areas. The Social Domain theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Social Domain Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Trending Equities.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
To fully project Candel Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Candel Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Candel Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Candel Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Candel Therapeutics investors may work on each financial statement separately, they are all related. The changes in Candel Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Candel Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.